TENAX THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
TENAX THERAPEUTICS, INC. (TENX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$10.07 million for the 8-month period ending 2015-12-31, per its 10-KT filed 2016-03-14.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2016-03-14
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2015-04-30 was -$4.99M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2015-01-31 was -$2.87M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2014-10-31 was -$4.05M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2014-07-31 was -$2.17M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$14.08M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$25.35M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2013 was -$11.76M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2012 was -$19.53M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 8 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2015-12-31 | -$10.07M 10-KT · filed 2016-03-14 | |||||
| 2015-04-30 | -$4.99M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | -$7.86M derived: sum of 2 quarters · filed 2016-03-14 | -$11.91M derived: sum of 3 quarters · filed 2016-03-14 | -$14.08M 10-KT · filed 2016-03-14 | ||
| 2015-01-31 | -$2.87M 10-Q · filed 2015-03-17 | -$6.92M derived: sum of 2 quarters · filed 2015-03-17 | -$9.09M 10-Q · filed 2015-03-17 | -$19.44M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-10-31 | -$4.05M 10-Q · filed 2014-12-15 | -$6.23M 10-Q · filed 2014-12-15 | -$16.57M derived: sum of 3 quarters · filed 2016-03-14 | -$21.05M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-07-31 | -$2.17M 10-Q · filed 2014-09-15 | -$12.51M derived: sum of 2 quarters · filed 2016-03-14 | -$17.00M derived: sum of 3 quarters · filed 2016-03-14 | -$23.18M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-04-30 | -$10.34M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | -$14.83M derived: sum of 2 quarters · filed 2016-03-14 | -$21.01M derived: sum of 3 quarters · filed 2016-03-14 | -$25.35M 10-KT · filed 2016-03-14 | ||
| 2014-01-31 | -$4.48M 10-Q · filed 2015-03-17 | -$10.66M derived: sum of 2 quarters · filed 2015-03-17 | -$15.00M 10-Q · filed 2015-03-17 | -$19.79M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2013-10-31 | -$6.18M 10-Q · filed 2014-12-15 | -$10.52M 10-Q · filed 2014-12-15 | -$15.30M derived: sum of 3 quarters · filed 2016-03-14 | -$20.21M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2013-07-31 | -$7.42M 10-Q · filed 2014-09-15 | -$9.12M derived: sum of 2 quarters · filed 2016-03-14 | -$14.03M derived: sum of 3 quarters · filed 2016-03-14 | -$18.53M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2013-04-30 | -$1.70M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | -$6.61M derived: sum of 2 quarters · filed 2016-03-14 | -$11.11M derived: sum of 3 quarters · filed 2016-03-14 | -$11.76M 10-KT · filed 2016-03-14 | ||
| 2013-01-31 | -$4.91M 10-Q · filed 2014-03-17 | -$9.41M derived: sum of 2 quarters · filed 2014-03-17 | -$10.05M 10-Q · filed 2014-03-17 | -$18.54M derived: sum of 4 quarters · filed 2014-03-17 | ||
| 2012-10-31 | -$4.50M 10-Q · filed 2013-12-17 | -$4.49M 10-Q · filed 2012-12-14 | -$8.08M 10-Q · filed 2013-12-17 | -$13.63M derived: sum of 3 quarters · filed 2013-12-17 | -$25.19M derived: sum of 4 quarters · filed 2013-12-17 | |
| 2012-07-31 | -$6.96M 10-Q · filed 2013-09-17 | -$9.14M derived: sum of 2 quarters · filed 2013-09-17 | -$20.69M derived: sum of 3 quarters · filed 2013-09-17 | -$28.26M derived: sum of 4 quarters · filed 2013-09-17 | ||
| 2012-04-30 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-26 | -$13.73M derived: sum of 2 quarters · filed 2013-06-26 | -$21.30M derived: sum of 3 quarters · filed 2013-06-26 | -$19.53M 10-K · filed 2013-06-26 | ||
| 2012-01-31 | -$11.56M 10-Q · filed 2013-03-18 | -$19.12M derived: sum of 2 quarters · filed 2013-03-18 | -$17.36M 10-Q · filed 2013-03-18 | |||
| 2011-10-31 | -$7.57M 10-Q · filed 2012-12-14 | -$10.44M 10-Q · filed 2012-12-14 | ||||
| 2011-07-31 | -$7.94M 10-Q · filed 2012-09-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |